Robert F Hobbs

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Calculation of the biological effective dose for piecewise defined dose-rate fits
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 36:904-7. 2009
  2. ncbi request reprint Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
    J Nucl Med 54:1535-42. 2013
  3. pmc A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD, USA
    Phys Med Biol 57:3207-22. 2012
  4. pmc A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 57:4403-24. 2012
  5. pmc A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 80:1256-62. 2011
  6. pmc Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma
    Srinivasan Senthamizhchelvan
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    J Nucl Med 53:215-24. 2012
  7. pmc Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore Maryland 21231, USA
    J Nucl Med 51:368-75. 2010
  8. pmc A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 38:2892-903. 2011
  9. pmc Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 116:5470-8. 2010
  10. pmc Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan
    Sébastien Baechler
    The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Cancer Biother Radiopharm 23:633-9. 2008

Collaborators

Detail Information

Publications25

  1. pmc Calculation of the biological effective dose for piecewise defined dose-rate fits
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 36:904-7. 2009
    ..The algorithmically calculated BED is compatible with an analytic calculation for a similarly valued exponentially fitted dose-rate plot and is the only resolution for piecewise defined dose-rate functions...
  2. ncbi request reprint Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
    J Nucl Med 54:1535-42. 2013
    ..We have developed such a methodology and applied it to hypothetical myeloablative treatment of non-Hodgkin lymphoma (NHL) patients using (131)I-tositumomab and (90)Y-ibritumomab tiuxetan...
  3. pmc A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD, USA
    Phys Med Biol 57:3207-22. 2012
    ..These suggest that increasing the amount of radioactivity may not substantially increase the risk of toxicity, a result unavailable to the absorbed fraction method of dose calculation...
  4. pmc A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 57:4403-24. 2012
    ..The S-values established here will enable a MIRD-type application of α-particle dosimetry for α-emitters, i.e. measuring the TIA in the kidney (or renal cortex) will provide meaningful and accurate nephron-level dosimetry...
  5. pmc A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 80:1256-62. 2011
    ..We have developed and tested a treatment planning method, using the patient-specific three-dimensional dosimetry package 3D-RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk...
  6. pmc Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma
    Srinivasan Senthamizhchelvan
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    J Nucl Med 53:215-24. 2012
    ..We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response...
  7. pmc Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore Maryland 21231, USA
    J Nucl Med 51:368-75. 2010
    ..Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with (131)I-tositumomab...
  8. pmc A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 38:2892-903. 2011
    ..The authors present here an adaptation of the simple sphere-based model from which cellular level dosimetry for macroscopic tumors and their end point quantities, such as TCP, may be extrapolated more reliably...
  9. pmc Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 116:5470-8. 2010
    ..The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities...
  10. pmc Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan
    Sébastien Baechler
    The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Cancer Biother Radiopharm 23:633-9. 2008
    ....
  11. pmc A gamma camera count rate saturation correction method for whole-body planar imaging
    Robert F Hobbs
    Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 55:817-31. 2010
    ..e. time-dependent dead-time effects. The algorithm presented here accomplishes this task...
  12. pmc Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y
    Hong Song
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 69:8941-8. 2009
    ..These data suggest (225)Ac-labeled anti-HER-2/neu monoclonal antibody could significantly prolong survival in HER-2/neu-positive metastatic breast cancer patients...
  13. pmc 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 50:1844-7. 2009
    ..A retrospective analysis of the conventional methodologies with appropriate corrections yielded absorbed dose estimates consistent with 3D-RD...
  14. pmc Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry
    Andrew R Prideaux
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 48:1008-16. 2007
    ..The methodology is illustrated using data from a thyroid cancer patient treated with radioiodine...
  15. pmc Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
    George Sgouros
    The Russell H Morgan Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Eur J Nucl Med Mol Imaging 38:S41-7. 2011
    ..We highlight specific examples of such calculations and discuss the potential impact of (124)I PET/CT on thyroid cancer therapy...
  16. doi request reprint Improved dose-volume histogram estimates for radiopharmaceutical therapy by optimizing quantitative SPECT reconstruction parameters
    Lishui Cheng
    The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Phys Med Biol 58:3631-47. 2013
    ..Optimal results were obtained with different parameters at each time point, but using a single set of parameters for all time points produced near-optimal dose-volume histograms...
  17. ncbi request reprint Modelling and dosimetry for alpha-particle therapy
    George Sgouros
    Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Curr Radiopharm 4:261-5. 2011
    ..These considerations along with a discussion of the appropriate physical quantity and related units for alpha-particle radiopharmaceutical therapy are examined in this review...
  18. pmc Human biodistribution and radiation dosimetry of 82Rb
    Srinivasan Senthamizhchelvan
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Nucl Med 51:1592-9. 2010
    ..Prior estimates of radiation-absorbed doses from (82)Rb, a frequently used PET perfusion tracer, yielded discrepant results. We reevaluated (82)Rb dosimetry using human in vivo biokinetic measurements...
  19. pmc Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
    Sébastien Baechler
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 35:1123-34. 2008
    ..The MIRD-based BED formalism is expected to be useful for patient-specific adjustments of activity and to facilitate the investigation of dose-toxicity correlations with respect to dose-rate and tissue repair mechanism...
  20. ncbi request reprint Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy
    Robert F Hobbs
    a Department of Radiology, Johns Hopkins University, School of Medicine, Baltimore Maryland
    Radiat Res 181:90-8. 2014
    ....
  21. pmc An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer
    Hong Song
    Division of Nuclear Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Cancer Res 14:6116-24. 2008
    ..We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies...
  22. pmc Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 115:2514-22. 2009
    ..The purpose of the current study was to determine the maximally tolerated dose of (153)Sm-EDTMP that permits hematopoietic recovery within 6 weeks...
  23. pmc Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
    De Xue Fu
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Nat Med 14:1118-22. 2008
    ..Bortezomib-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy...
  24. ncbi request reprint Dosimetry for radiopharmaceutical therapy
    George Sgouros
    Johns Hopkins University, Baltimore, Md Electronic address
    Semin Nucl Med 44:172-8. 2014
    ....
  25. ncbi request reprint The role of preclinical models in radiopharmaceutical therapy
    George Sgouros
    From the Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD
    Am Soc Clin Oncol Educ Book 34:e121-5. 2014
    ..RPT is a distinct therapeutic modality whose mechanism of action is well understood. Measurements can be made in preclinical models to help guide clinical implementation of RPT and optimize combination therapy using RPT. ..